^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MGY825

    i
    Other names: MGY825, MGY-825, MGY 825
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    NRF2 inhibitor, CUL3 inhibitor, KARS inhibitor, KEAP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=41, Terminated, Novartis Pharmaceuticals | N=140 --> 41 | Trial completion date: Jul 2027 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jul 2027 --> Oct 2025; The trial was terminated due to a business decision and not as a result of any safety concerns
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KEAP1 mutation • NFE2L2 mutation
    |
    MGY825
    1year
    Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=140, Recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: Aug 2026 --> Jul 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KEAP1 mutation • NFE2L2 mutation
    |
    MGY825
    over2years
    Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=140, Recruiting, Novartis Pharmaceuticals | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KEAP1 mutation • NFE2L2 mutation
    |
    MGY825
    over2years
    Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=1, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2025 --> Aug 2026 | Trial primary completion date: Feb 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KEAP1 mutation • NFE2L2 mutation
    |
    MGY825
    almost3years
    Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=1, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=140 --> 1
    Enrollment closed • Enrollment change • Metastases
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KEAP1 mutation • NFE2L2 mutation
    |
    MGY825
    over3years
    Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=140, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KEAP1 mutation • NFE2L2 mutation
    |
    MGY825
    almost4years
    Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=140, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KEAP1 mutation • NFE2L2 mutation
    |
    MGY825